Literature DB >> 17003380

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

Kirk R Schultz1, D Jeanette Pullen, Harland N Sather, Jonathan J Shuster, Meenakshi Devidas, Michael J Borowitz, Andrew J Carroll, Nyla A Heerema, Jeffrey E Rubnitz, Mignon L Loh, Elizabeth A Raetz, Naomi J Winick, Stephen P Hunger, William L Carroll, Paul S Gaynon, Bruce M Camitta.   

Abstract

The Children's Cancer Group (CCG) and the Pediatric Oncology Group (POG) joined to form the Children's Oncology Group (COG) in 2000. This merger allowed analysis of clinical, biologic, and early response data predictive of event-free survival (EFS) in acute lymphoblastic leukemia (ALL) to develop a new classification system and treatment algorithm. From 11 779 children (age, 1 to 21.99 years) with newly diagnosed B-precursor ALL consecutively enrolled by the CCG (December 1988 to August 1995, n=4986) and POG (January 1986 to November 1999, n=6793), we retrospectively analyzed 6238 patients (CCG, 1182; POG, 5056) with informative cytogenetic data. Four risk groups were defined as very high risk (VHR; 5-year EFS, 45% or below), lower risk (5-year EFS, at least 85%), and standard and high risk (those remaining in the respective National Cancer Institute [NCI] risk groups). VHR criteria included extreme hypodiploidy (fewer than 44 chromosomes), t(9;22) and/or BCR/ABL, and induction failure. Lower-risk patients were NCI standard risk with either t(12;21) (TEL/AML1) or simultaneous trisomies of chromosomes 4, 10, and 17. Even with treatment differences, there was high concordance between the CCG and POG analyses. The COG risk classification scheme is being used for division of B-precursor ALL into lower- (27%), standard- (32%), high- (37%), and very-high- (4%) risk groups based on age, white blood cell (WBC) count, cytogenetics, day-14 marrow response, and end induction minimal residual disease (MRD) by flow cytometry in COG trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003380      PMCID: PMC1785141          DOI: 10.1182/blood-2006-01-024729

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia.

Authors:  J L Wiemels; R N Smith; G M Taylor; O B Eden; F E Alexander; M F Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.

Authors:  G H Reaman; R Sposto; M G Sensel; B J Lange; J H Feusner; N A Heerema; M Leonard; E J Holmes; H N Sather; T W Pendergrass; H S Johnstone; R T O'Brien; P G Steinherz; P M Zeltzer; P S Gaynon; M E Trigg; F M Uckun
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

3.  The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.

Authors:  C Patte; A Auperin; J Michon; H Behrendt; G Leverger; D Frappaz; P Lutz; C Coze; Y Perel; M Raphaël; M J Terrier-Lacombe
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

4.  A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.

Authors:  S J Lauer; J J Shuster; D H Mahoney; N Winick; S Toledano; L Munoz; G Kiefer; J D Pullen; C P Steuber; B M Camitta
Journal:  Leukemia       Date:  2001-07       Impact factor: 11.528

5.  Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes).

Authors:  N A Heerema; H N Sather; M G Sensel; T Zhang; R J Hutchinson; J B Nachman; B J Lange; P G Steinherz; B C Bostrom; G H Reaman; P S Gaynon; F M Uckun
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

6.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

Authors:  P S Gaynon; M E Trigg; N A Heerema; M G Sensel; H N Sather; G D Hammond; W A Bleyer
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

7.  Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994.

Authors:  K W Maloney; J J Shuster; S Murphy; J Pullen; B A Camitta
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

8.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

Authors:  Vassilios I Avramis; Susan Sencer; Antonia P Periclou; Harland Sather; Bruce C Bostrom; Lewis J Cohen; Alice G Ettinger; Lawrence J Ettinger; Janet Franklin; Paul S Gaynon; Joanne M Hilden; Beverly Lange; Fataneh Majlessipour; Pracad Mathew; Michael Needle; Joseph Neglia; Gregory Reaman; John S Holcenberg; Linda Stork
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

9.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  M Aricò; M G Valsecchi; B Camitta; M Schrappe; J Chessells; A Baruchel; P Gaynon; L Silverman; G Janka-Schaub; W Kamps; C H Pui; G Masera
Journal:  N Engl J Med       Date:  2000-04-06       Impact factor: 91.245

10.  Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).

Authors:  J Donadieu; M F Auclerc; A Baruchel; Y Perel; P Bordigoni; J Landman-Parker; T Leblanc; G Cornu; D Sommelet; G Leverger; G Schaison; C Hill
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  136 in total

Review 1.  [Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].

Authors:  Jin-Yun Xu; Jian-Ming Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Authors:  Melchior Lauten; Anja Möricke; Rita Beier; Martin Zimmermann; Martin Stanulla; Barbara Meissner; Edelgard Odenwald; Andishe Attarbaschi; Charlotte Niemeyer; Felix Niggli; Hansjörg Riehm; Martin Schrappe
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

3.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; Max Jan; Rachel Weissman-Tsukamoto; Feifei Zhao; Christopher Y Park; Irving L Weissman; Ravindra Majeti
Journal:  Cancer Res       Date:  2010-12-21       Impact factor: 12.701

4.  Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.

Authors:  Etan Orgel; Richard Sposto; Jemily Malvar; Nita L Seibel; Elena Ladas; Paul S Gaynon; David R Freyer
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

5.  The use of central laboratories and remote electronic data capture to risk-adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma.

Authors:  Meenakshi Devidas; Wendy B London; James R Anderson
Journal:  Semin Oncol       Date:  2010-02       Impact factor: 4.929

6.  Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.

Authors:  Jun J Yang; Cheng Cheng; Wenjian Yang; Deqing Pei; Xueyuan Cao; Yiping Fan; Stanley B Pounds; Geoffrey Neale; Lisa R Treviño; Deborah French; Dario Campana; James R Downing; William E Evans; Ching-Hon Pui; Meenakshi Devidas; W P Bowman; Bruce M Camitta; Cheryl L Willman; Stella M Davies; Michael J Borowitz; William L Carroll; Stephen P Hunger; Mary V Relling
Journal:  JAMA       Date:  2009-01-28       Impact factor: 56.272

7.  Detection of acquired hemoglobinopathy in children with hematological malignancies at disease onset: results form a national referral centre.

Authors:  Despoina N Maritsi; Helen V Kosmidis; Varvara Douna; Joanne Traeger-Synodinos; Maria N Tsolia; Lydia Kossiva
Journal:  Int J Hematol       Date:  2013-10-05       Impact factor: 2.490

Review 8.  Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.

Authors:  Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

9.  Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.

Authors:  Ravin Garg; Hagop Kantarjian; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Denise Lovshe; Sherry Pierce; Susan O'Brien
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

Review 10.  High-risk childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Scott C Howard; Ching-Hon Pui
Journal:  Clin Lymphoma Myeloma       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.